Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12030770 | 0.82 | ALDH1A1 (0.42) | CYP2D6ALDH1A1KDM4EKMT2A | |
| SCHEMBL8437435 | 0.81 | ALDH1A1 (0.55) | CYP2D6ALDH1A1KDM4EKMT2A | |
| SCHEMBL8259518 | 0.79 | ALDH1A1 (0.40) | CYP2D6ALDH1A1KDM4EKMT2A | |
| SCHEMBL8443208 | 0.79 | ALDH1A1 (0.47) | CYP2D6ALDH1A1KDM4EKMT2A | |
| SCHEMBL12258804 | 0.79 | ALDH1A1 (0.51) | CYP2D6ALDH1A1KDM4EKMT2A | |
| SCHEMBL13600121 | 0.77 | KDM4E (0.50) | KDM4EKMT2A | |
| SCHEMBL12870586 | 0.77 | ALDH1A1 (0.50) | CYP2D6ALDH1A1KDM4EKMT2A | |
| SCHEMBL8193648 | 0.77 | ALDH1A1 (0.50) | CYP2D6ALDH1A1KDM4EKMT2A | |
| SCHEMBL12869546 | 0.75 | ALDH1A1 (0.49) | CYP2D6ALDH1A1KDM4EKMT2A | |
| SCHEMBL4833027 | 0.73 | KDM4E (0.42) | CYP2D6ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| CN-1768061-A | Pyrazolo[1,5-a][1,3,5]triazine derivatives as cannabinoid receptor ligands | PFIZER PROD INC (US) | 2006-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | CYP2D6 934/4885ALDH1A1 526/4885KDM4E 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.